Magpie Diagnostics
Lung

EGFR Mutation Testing in Non–Small Cell Lung Cancer: A Predictive Biomarker Primer

What EGFR mutation testing measures and what it determines for treatment eligibility.

✓ Medically reviewedApril 25, 20265 min read
Share

What the Test Measures

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that sits on the cell surface and, when activated, drives signaling cascades governing proliferation and survival. In a subset of lung adenocarcinomas, the EGFR gene carries somatic mutations that lock this kinase into a constitutively "on" state, the tumor no longer waits for an external ligand to grow. These are oncogenic driver mutations, and their importance is twofold: they help explain the tumor's biology, and they predict whether the cancer will respond to drugs designed to shut that kinase down [1,2][4].

That predictive role is what makes EGFR testing a companion to therapy rather than a purely descriptive exercise. We're not naming the mutation; we're asking whether it opens a door to a specific class of targeted agents.

How It's Tested

EGFR status can be determined on formalin-fixed, paraffin-embedded (FFPE) tumor tissue or on cell-free circulating tumor DNA (ctDNA) extracted from plasma. Two broad assay platforms dominate: next-generation sequencing (NGS), which surveys many genes and mutation types at once, and targeted PCR-based assays, which interrogate a defined panel of known hotspots [1][7][8][9].

Each specimen type carries preanalytic constraints that matter. FFPE tissue depends on adequate tumor cellularity and reasonable DNA quality; a scant or heavily necrotic biopsy can yield a false-negative because there isn't enough amplifiable template. Plasma ctDNA is attractive when tissue is exhausted or the patient can't safely be re-biopsied, but its sensitivity depends on how much tumor DNA is shedding into the circulation. Low-shedding tumors can produce a negative plasma result that doesn't reflect the true tissue genotype. In practice, this means a negative ctDNA result rarely closes the question, tissue confirmation is often the next step [7][8].

Scoring here isn't a percentage or an intensity score, as it would be for an immunohistochemical stain. What matters is which mutation is present, because different alterations carry entirely different clinical meanings.

Interpreting the Result States

The following categories capture the clinically actionable landscape, along with what each one tells us:

  • Exon 19 deletion / L858R (classic sensitizing). These are the two canonical activating mutations. They predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs) and together account for the majority of driver-positive cases [1,3][4][5][6].
  • Exon 20 insertion. A biologically distinct group. These insertions generally don't respond to the classic sensitizing-mutation TKIs and instead inform eligibility for a separate set of agents, notably amivantamab, developed specifically for exon 20 disease; NGS is required because targeted PCR misses roughly half of these insertions [1][10][11].
  • T790M (acquired resistance). This variant typically emerges after treatment, as a mechanism by which a previously responsive tumor escapes an earlier-generation TKI. Detecting it at progression reshapes the interpretation of the case [1][12].
  • Atypical mutations (S768I, L861Q, G719X). These uncommon variants sit in a grey zone. Some confer TKI sensitivity, though the supporting data are thinner and less uniform than for the classic pair [1].
  • Wild-type. No actionable EGFR mutation detected, a result that redirects the diagnostic workup toward other drivers and, importantly, must be read in light of assay sensitivity.

The interpretive point that trainees sometimes miss: "EGFR-mutant" is not one thing. An exon 19 deletion and an exon 20 insertion are both EGFR mutations, yet they gate different drugs. Lumping them together is a genuine clinical error.

What It Determines for Treatment Eligibility

Classic sensitizing mutations, exon 19 deletions and L858R, inform eligibility for EGFR TKIs, including osimertinib [1,3]. Exon 20 insertions inform eligibility for the distinct class of agents developed for that variant. T790M, when it appears at progression, points toward a different resistance-directed strategy. Framed carefully: the biomarker establishes eligibility for a drug class; it does not prescribe an individual patient's regimen, which remains a clinical decision made with the treating team.

The relevance of EGFR status extends beyond metastatic disease, and this catches many trainees off guard. Mutation testing carries adjuvant implications in earlier-stage resected disease, and there are indications in stage III disease following chemoradiotherapy [1]. In other words, a patient with a surgically resected tumor or locally advanced disease may still have their management informed by EGFR genotype, so the question of whether to test should not be reflexively restricted to advanced-stage cases. The evidence supporting these settings continues to mature, but the practical takeaway is that a negative habit of "test only in stage IV" risks missing eligible patients.

Caveats and What's Evolving

A few points stand out. First, the atypical variants remain an area of genuine uncertainty; the data guiding their management are less solid, and interpretation should acknowledge that openly [1]. Second, ctDNA's limitations cut in one direction, a positive plasma result is informative, but a negative one may reflect low tumor shedding rather than true absence of a mutation.

Finally, testing at a single time point rarely tells the whole story. EGFR-mutant tumors evolve under treatment pressure, and re-testing at progression, whether on tissue or plasma, can reveal acquired resistance mechanisms such as T790M that weren't present at baseline. Co-occurring alterations detected on broad NGS panels can also modify how a given EGFR result should be interpreted, since additional drivers or resistance markers may complicate the clinical picture. That's the underappreciated lesson of EGFR diagnostics: the genotype is a moving target, and yesterday's result doesn't always describe today's tumor.

References

  1. Review. Lung Cancer: Targeted Therapy in 2025. Curr Oncol. 2025. PMC11941068.
  2. WHO Classification of Tumours Editorial Board. Thoracic Tumours, 5th ed. IARC, Lyon; 2021. ISBN 978-92-832-4506-3. (Classification/biology background only; not a diagnostic-performance source.)
  3. Fehrenbacher L, et al. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non, small-cell lung cancer. 2017. PMCID: PMC5650459.
  4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin, paclitaxel in pulmonary adenocarcinoma (IPASS). N Engl J Med. 2009;361(10):947-957. PMID: 19692680. doi:10.1056/NEJMoa0810699.
  5. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non, small-cell lung cancer (FLAURA). N Engl J Med. 2018;378(2):113-125. PMID: 29151359. doi:10.1056/NEJMoa1713137.
  6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non, small-cell lung cancer (EURTAC). Lancet Oncol. 2012;13(3):239-246. PMID: 22285168. doi:10.1016/S1470-2045(11)70393-X.
  7. Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status (IFUM). Br J Cancer. 2014;110(1):55-62. PMID: 24263064. doi:10.1038/bjc.2013.721.
  8. Mok T, Wu YL, Lee JS, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy (FASTACT-2). Clin Cancer Res. 2015;21(14):3196-3203. PMID: 25829397. doi:10.1158/1078-0432.CCR-14-2594.
  9. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC (FLAURA2). N Engl J Med. 2023;389(21):1935-1948. PMID: 37937763. doi:10.1056/NEJMoa2306434.
  10. Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions (PAPILLON). N Engl J Med. 2023;389(22):2039-2051. PMID: 37870976. doi:10.1056/NEJMoa2306441.
  11. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion, mutated non, small-cell lung cancer progressing on platinum chemotherapy (CHRYSALIS). J Clin Oncol. 2021;39(30):3391-3402. PMID: 34339292. doi:10.1200/JCO.21.00662.
  12. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum, pemetrexed in EGFR T790M, positive lung cancer (AURA3). N Engl J Med. 2017;376(7):629-640. PMID: 27959700. doi:10.1056/NEJMoa1612674.
  13. Cho BC, Han JY, Kim SW, et al. Osimertinib for patients with non, small-cell lung cancer harboring uncommon EGFR mutations (KCSG-LU15-09). J Clin Oncol. 2020;38(5):488-495. PMID: 31825714. doi:10.1200/JCO.19.00931.
  14. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non, small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, 3 and 6. Lancet Oncol. 2015;16(7):830-838. PMID: 26051236. doi:10.1016/S1470-2045(15)00026-1.
  15. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non, small-cell lung cancer (ADAURA). N Engl J Med. 2020;383(18):1711-1723. PMID: 32955177. doi:10.1056/NEJMoa2027071.
  16. Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC (LAURA). N Engl J Med. 2024;391(7):585-597. PMID: 38828946. doi:10.1056/NEJMoa2402614.

Tags

biomarkertesting